Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MCI Group Canada. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation Provider Number: 4008163 Professions in scope for this activity are listed here.

Physicians
Amedco LLC designates this live activity for a maximum of 17.00 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Time Location Name Name Description Speakers
5:00 PM - 6:30 PMSacramentoPLENARY 1 - A Focus On Where We are At
  • Opening remarks John Ward and Norah Terrault
  • ISVHLD Remarks Harry Janssen
  • John Martin Foundation, The Raymond F. Schinazi & Family Foundation & Stephan Urban Award Ceremony John Ward, Norah Terrault, Harry Janssen, Ralf Bartenschlager
  • Bridging basic-clinical-implementation spheres in viral hepatitis + Q&A Jordan Feld
  • Global progress on hepatitis B, C, and D elimination + Q&A Meg Doherty, Funmi Lesi
  • PANEL: Challenges on transitions of the US government and implications for hepatitis elimination in the US and global Su Wang
Time Location Name Name Description Speakers
7:00 AM - 8:00 AMSan JoseBREAKFAST SYMPOSIUM 
8:30 AM - 10:00 AMSan JoseCLINICAL PARALLEL 1 - Management of HBV in 2025

Moderator: Kosh Agarwal

  • Interferon as a Component of HBV Cure in 2024 and 2034  Harry Janssen
  • Oral Presentation: IMMUNE SIGNATURE ASSOCIATED WITH VIRAL SUPPRESSION FOLLOWING NUCLEOS(T)IDE ANOLOGUE TREATMENT IN ADULTS LIVING WITH CHRONIC HBV INFECTION IN SOUTH AFRICA Marion Delphin
  • Oral Presentation: SIMILAR RATES OF BIOCHEMICAL RESPONSE ARE OBSERVED ACROSS VIROLOGIC RESPONSE CATEGORIES OVER 96 WEEKS OF BULEVIRTIDE Pietro Lampertico
  • Oral Presentation: FACTORS INFLUENCING HEPATITIS B SPECIALITY CARE REFERRAL AMONG REFUGEES RECENTLY RESETTLED TO THE UNITED STATES Erin Mann
  • Oral Presentation: CHALLENGES AND OPPORTUNITIES FOR REENGAGING DIAGNOSED BUT UNTREATED HBV/HCV-INFECTED INDIVIDUALS IN THE UNITED STATES TO CARE (PRELIMINARY RESULTS FROM A MULTI-CENTER RELINK PROGRAM) Helen Nde
  • Q&A
8:30 AM - 10:00 AMSacramentoCLINICAL PARALLEL 2 - Practical Strategies for implementing Guidelines and Maximizing Treatment Outcomes

Moderator: Anna Lok

  • How to Engage and Support Priority Populations for Viral Hepatitis Care in Non-Endemic Regions Christina Greenway 
  • Patient and Provider Perspective on Overcoming Barriers to Care Su Wang
  • Oral Presentation: FACTORS INFLUENCING ANTIVIRAL MEDICATION ADHERENCE AMONG CHRONIC HEPATITIS B PATIENTS IN ADDIS ABABA: A MULTICENTER CROSS-SECTIONAL STUDY  Kaleb Berhane
  • Oral Presentation: DEVELOPMENT AND IMPLEMENTATION OF AN HEPATITIS D DETECTION AND LINKAGE TO CARE PROGRAM IN CATALONIA. PRELIMINARY RESULTS.  Maria Buti
  • Oral Presentation: IMPACT OF SYSTEMATIC SCREENING FOR VIRAL HEPATITIS IN THE ED: A FOUR-YEAR PROSPECTIVE STUDY Maria Buti 
  • Q&A
8:30 AM - 10:00 AMSan DiegoPUBLIC HEALTH PARALLEL 0 - Oral Presentations: Epidemiological Trends to Inform Policy Change

Moderator: Junko Tanaka

  • Oral Presentation: PREVALENCE AND CORRELATES OF HEPATITIS C IN A MALAYSIAN PRISON Mahija Ginjupalli
  • Oral Presentation: PREVALENCE OF HBV AND HCV INFECTIONS AMONG AT-RISK MIGRANT AND REFUGEE POPULATIONS IN GREECE, ITALY AND SPAIN: 2-YEAR RESULTS OF THE VH-COMSAVAC PROJECT Camila Picchio
  • Oral Presentation: INTERVENTIONS TO IMPROVE TESTING, LINKAGE TO CARE, AND TREATMENT UPTAKE FOR HEPATITIS C INFECTION IN PRISON: A SYSTEMATIC REVIEW Jason Grebely
  • Oral Presentation: ANTEPARTUM HEPATITIS C VIRUS SCREENING AT AN URBAN ACADEMIC MEDICAL CENTER BEFORE AND AFTER THE 2021 AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS UNIVERSAL SCREENING RECOMMENDATIONS Michelle Martin
    Oral Presentation: SMART-C ®, A NOVEL ONE STEP POINT OF CARE TEST FOR DETECTION OF HCV ANTIGENS COMPARED TO POLYMERASE CHAIN REACTION (PCR). Ayman Hassan
  • Q&A
8:30 AM - 10:00 AMBeverlyPUBLIC HEALTH PARALLEL 1 - Interventions to prevent viral hepatitis

Moderator: Keo Samley

  • Prevention of hepatitis B and D (including PMTCT- increasing HBV birth dose, novel strategies to treat any woman HbsAg+ if no HBV DNA or birth dose available) Ben Cowie 
  • Prevention of hepatitis C (focus on PWID – known interventions that are effective, such as opioid agonist treatment and syringe service programs) Julie Bruneau
  • Oral Presentation: MODELING THE EFFECT OF TARGETED INTERVENTIONS ON THE SPREAD OF HEPATITIS C THROUGH A NETWORK OF PEOPLE WHO INJECT DRUGS IN KENYA Ewan Colman
  • Oral Presentation: OPTIMIZING TESTING AND TREATMENT STRATEGIES FOR HEPATITIS C ELIMINATION IN PUNJAB, PAKISTAN; REPORT FROM HEPATITIS PREVENTION AND TREATMENT PROGRAM Saeed Akhter
  • Oral Presentation: IMPACT OF A TREATMENT PEER-SUPPORT MODEL ON HEPATITIS B SCREENING AND LINKAGE TO INTEGRATED HIV/HBV CARE IN A HIGH BURDEN HBV SETTING IN NORTHERN UGANDA Joan J. Mutyoba
  • Oral Presentation: CHARACTERIZING ENGAGEMENT IN HEPATITIS C VIRUS TESTING AND CARE FOR INFANTS BORN TO PERSONS WHO TEST POSITIVE FOR HCV IN ONTARIO, CANADA Andrew B. Mendlowitz
  • Q&A
10:30 AM - 12:00 PMSacramentoPLENARY 2 - State of the Art: Report Card on Drug Development for HBV: Lessons Learned and the Path Forward

Moderators: John Ward & Norah Terrault

  • Report Card on Drug Development for HBV: Lessons Learned and the Path Forward + Q&A  Ed Gane
  • Oral Presentation: ANTI-HBSAG MONOCLONAL ANTIBODY BJT-778 DEMONSTRATES PANGENOTYPIC NEUTRALIZATION OF HEPATITIS B AND D VIRUSES  + Q&A Ronald Alcala
  • Oral Presentation: HBSAG LOSS IN INACTIVE CHRONIC HEPATITIS B CARRIERS IS DEPENDENT ON LEVEL OF QHBSAG AND INTERFERON RESPONSE: A RANDOMISED CONTROL TRIAL + Q&A  Seng Gee Lim
  • Introductory Talk: Current & future therapies from a global perspective (challenges & barriers) Funmi Lesi
  • Panel - HBV Therapeutics (what's needed now and in the future) + Q&A
12:00 PM - 1:00 PMSan JoseLUNCH SYMPOSIUM 
1:30 PM - 3:00 PMSan DiegoBASIC PARALLEL 1 - MishMASH: molecular mechanisms for liver disease

Moderator: Andrea Cox

  • MASH: molecular underpinnings of novel therapeutics Percy Knolle 
  • Lipoproteins and their role in hepatitis virus replication and liver disease Ralf Bartenschlager
  • Oral Presentation: A MOST RELEVANT MODEL OF HEPATITIS C VIRUS (HCV) INFECTION IN PRIMARY HUMAN HEPATOCYTES REVEALS THAT ALCOHOL INCREASES THE PRODUCTION OF BOTH VERY-LOW-DENSITY LIPOPROTEINS (VLDL) AND HIGHLY INFECTIOUS LIPO-VIRO-PARTICLES Arielle Rosenberg 
  • Oral Presentation: EVALUATION OF CELL FREE DNA METHYLATION AS LIQUID BIOPSY BIOMARKER TO DIFFERENTIATE HEPATITIS B VIRUS INDUCED HEPATOCELLULAR CARCINOMA FROM CHRONIC LIVER DISEASE Baibaswata Nayak
  • Q&A
1:30 PM - 3:00 PMSacramentoCLINICAL PARALLEL 3 - ILCA-GHS HCC Symposium

Moderator: Ju Dong Yang & Seng Gee Lim

  • Risk stratification – HBV and post-SVR  Nicole Kim
  • Debate – Are there patients that we can stop surveillance in low risk patients? Neil Mehta, Nicole Kim
  • Early detection/screening – surveillance underuse and emerging modalities Ju Dong Yang
  • Panel – implementation of these strategies   Neil Mehta, Nicole Kim, Ju Dong Yang
1:30 PM - 3:00 PMBeverlyPUBLIC HEALTH PARALLEL 2 - Screening and diagnosis of viral hepatitis (Identifying the right test, for the right patient, in the right setting)

Moderator: Wendy Spearman

  • Optimising strategies to enhance screening and diagnosis for hepatitis B Jean-Michel Pawlotsky 
  • Optimising strategies to enhance screening and diagnosis for hepatitis C John Ward
  • Oral Presentation: EFFECTIVENESS OF HEALTH SYSTEM INTERVENTIONS ON UPTAKE OF HEPATITIS C SELF-TESTING (HCV-ST) IN URBAN SLUMS OF HARIDWAR: A PRAGMATIC CLUSTER RANDOMIZED CONTROL TRIAL Ajeet Singh
  • Oral Presentation: LOW LEVELS OF VIRAL HEPATITIS AWARENESS, TESTING, AND HBV VACCINATION AMONG AT-RISK MIGRANT AND REFUGEE POPULATIONS IN GREECE, ITALY AND SPAIN: RESULTS FROM VH-COMSAVAC Camilla Picchio
  • Oral Presentation: BENDING THE CURVE OF HEPATITIS C VIRUS INFECTION IN MACHAR COLONY: A MASS SCREEN AND TREAT INTERVENTION IN A SLUM SETTLEMENT IN KARACHI, PAKISTAN Muhammad Khawar Aslam
  • Oral Presentation: PREP PROGRAMMES AS A FRAMEWORK FOR TACKLING HBV INFECTION IN ADOLESCENTS AND YOUNG ADULTS IN KWAZULU-NATAL, SOUTH AFRICA Gloria Sukali
  • Q&A
3:30 PM - 5:00 PMSan DiegoCLINICAL PARALLEL 4 - Optimizing HBV Treatment: Prospects for a functional cure

Moderator: Harry Janssen

  • Progress towards a Sterilizing Cure - Advances in Gene editing and Targeting cccDNA Fabien Zoulim
  • The Role of RNA interference (siRNA, ASO) as the backbone of HBV Cure strategies Kosh Agarwal
  • Therapeutic Vaccines and Other Immune Targets for Functional Cure, How Good is the Promise? Adam Gehring
  • Oral Presentation: ASSOCIATION OF HEPATITIS B SURFACE ANTIGEN LOSS WITH CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC HEPATITIS B INFECTION: A RETROSPECTIVE COHORT STUDY IN THE UNITED STATES Anna Coutinho
  • Oral Presentation: TREATMENT RELATED NORMALIZATION OF ALT IS ASSOCIATED WITH RESOLUTION OF SIGNIFICANT LIVER INFLAMMATION IN PATIENTS WITH CHRONIC HEPATITIS B Lisa van Velsen
  • Q&A
3:30 PM - 5:00 PMSacramentoCLINICAL PARALLEL 5 - Delta Therapies - Current and Future

Moderator: Jean-Michel Palowtsky

  • Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta Maria Buti
  • Overview of New Drug Development for Hepatitis Delta Pietro Lampertico
  • Management of Delta for indigenous populations Thor Dantas
  • Oral Presentation: EFFICACY AND SAFETY OF BLV MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: POSTTREATMENT RESULTS THROUGH 48 WEEKS AFTER THE END OF TREATMENT FROM AN INTERIM ANALYSIS OF A RANDOMIZED PHASE 3 STUDY MYR301 Pietro Lampertico
  • Q&A
3:30 PM - 5:00 PMBeverlyPUBLIC HEALTH PARALLEL 3 - Interventions to enhance testing, treatment, and viral elimination

Moderator: David Thomas

  • Interventions to enhance linkage to hepatitis C care and treatment (not diagnostic strategies - e.g. electronic medical record audit, financial incentives, peer support, pharmacy starter packs) Seun Falade-Nwulia 
  • Interventions to enhance linkage to hepatitis B & D care and treatment (not diagnostic strategies) Alexander Stockdale
  • Oral Presentation: LINKAGE TO CARE OF PEOPLE WHO INJECT DRUGS WITHIN NATIONAL HEPATITIS C ELIMINATION PROGRAM IN GEORGIA Maka Gogia
  • Oral Presentation: EVALUATING THE IMPACT OF INCREASED PROVISION OF LOW DEAD SPACE SYRINGES ON HIV AND HCV TRANSMISSION AMONG PEOPLE WHO INJECT DRUGS: A MODELLING ANALYSIS FOR 19 COUNTRIES Peter Vickerman
  • Oral Presentation: OPTIMIZING HEALTHCARE SYSTEMS FOR VIRAL HEPATITIS ELIMINATION: AUTOMATING EMR-BASED HEPATITIS B AND C SCREENING Su Wang
  • Oral Presentation: ACHIEVEMENTS AND CHALLENGES IN SCALING HCV SERVICES TO PRIMARY HEALTHCARE (PHC) FACILITIES IN CAMBODIA Alethea Tan
  • Q&A
Time Location Name Name Description Speakers
7:00 AM - 8:00 AMSan JoseBREAKFAST SYMPOSIUM 
8:30 AM - 10:00 AMSan DiegoBASIC PARALLEL 2 - Dueling virology: HBV and HDV

Moderator: Ulrike Protzer

  • Molecular basis for an HBV cure using antivirals Chloe Thio
  • From controlling HDV to HDV cure Marc Ghany
  • Oral Presentation: A NOVEL LONG-ACTING HBV/HDV ENTRY INHIBITOR Jimmy Zhang
  • Oral Presentation: DEVELOPMENT AND VALIDATION OF STREAMLINED SERODIAGNOSIS OF HEPATITIS DELTA VIRUS ND Dashdorj
  • Oral Presentation: EVALUATION OF MIR-122 SERUM EXPRESSION AMONG INDIVIDUALS WITH LONG COVID AND VIRAL HEPATITIS Livia Villar
  • Q&A
8:30 AM - 10:00 AMSacramentoCLINICAL PARALLEL 6 - HBV Treatment Challenges and Controversies

Moderator: Jennifer Price

  • Debate: Do Not Stop Long-Term NA Therapy in Absence of Functional Cure (against) Anna Lok
  • Debate: You Can Stop Long-Term Therapy in Absence of Functional Cure (for) Rachel Jeng
  • What is the Evidence for Expanding NA Therapy Patrick Kennedy
  • Oral Presentation: EARLY OFF-TREATMENT HBCRAG AND ANTI-HBC LEVELS IDENTIFY PATIENTS AT HIGH RISK OF SEVERE ALT FLARES AFTER NUCLEOS(T)IDE ANALOGUE WITHDRAWAL – A POOLED ANALYSIS OF TWO PROSPECTIVE STUDIES Edo Dongelmans
  • Oral Presentation: HEPATOCELLULAR CARCINOMA RISK IN HISPANICS WITH CHRONIC HEPATITIS B Ariel Lee
  • Oral Presentation: HBV-HIV CO-INFECTION & TENOFOVIR INTERRUPTION IN THE UNITED STATES: MONITORING PRACTICES AND INCIDENCE OF HEPATITIS B REACTIVATION OR HEPATITIS FLARE Douglas T. Dieterich
  • Q&A
8:30 AM - 10:00 AMBeverlyPUBLIC HEALTH PARALLEL 4 - Special Populations

Moderator: Norah Terrault

  • Essential role of harm reduction services in hepatitis C elimination in carceral settings: Why is the world so far behind? Nadine Kronfli
  • Addressing Challenges to Engage People who Use Drugs into Care - A Community Perspective Sione Crawford
  • Overseas born/refugees/migrants - Overview Camila Picchio
  • Collaborating with First Nations Communities to Enhance Hepatitis C Care Kate Dunn
  • Q&A
10:30 AM - 12:00 PMSacramentoPLENARY 3 - State of the Art: Thinking outside the Box for HCV: Treat to Cure and Eliminate

Moderator: John Ward & Norah Terrault

  • Thinking outside the Box for HCV: Treat to Cure and Eliminate + Q&A Margaret Hellard 
  • Oral Presentation: NEW HIV, HCV AND HBV INFECTIONS ATTRIBUTED TO UNSAFE MEDICAL INJECTIONS IN LOW AND MIDDLE-INCOME COUNTRIES: AN ANALYSIS BASED ON DEMOGRAPHIC AND HEALTH SURVEYS  + Q&A  Adelina Artenie
  • IMPACT OF PHARMACIST-LED HEPATITIS C SERVICE ON CURE RATES IN A FEDERALLY QUALIFIED HEALTH CENTER + Q&A Elma Abdullah
  • Pharmacology of long-acting HCV therapeutics Andrew Owen
  • Introductory Talk and Panel + Q&A Niklas Luhmann
12:00 PM - 1:00 PMSan JoseLUNCH SYMPOSIUM 
1:30 PM - 3:00 PMSan DiegoBASIC PARALLEL 3 - Exploiting adaptive immunity to combat viral hepatitis

Moderator: Adam Gehring

  • Restoring immunity to cure hepatitis B Ulrike Protzer
    Immunologic prescription for a vaccine to prevent chronic hepatitis C Andrea Cox 
  • Oral Presentation: MYELOID CELLS SUPPORT THE INDUCTION OF AUTO-AGGRESSIVE CD8 T CELLS IN CHRONIC HEPATITIS B Wei Ting (Jonah) Lin
  • Oral Presentation: SYNTHETIC INTERFERON EXHIBITS POTENT ANTIVIRAL ACTIVITY AGAINST HBV WITH THE POTENTIAL FOR AN IMPROVED SAFETY PROFILE Cheyne Kurokawa
  • Q&A
1:30 PM - 3:00 PMSacramentoCLINICAL PARALLEL 7 - New Diagnostics and Technologies in Liver Disease - Potential for Current and Future Clinical Practice

Moderator: Carla Coffin

  • Novel Biomarkers and Point of Care Tests for HBV management Lung Yi Mak
  • Application of Artifical Intelligence in Viral Hepatitis Terry Yip
  • Oral Presentation: PERFORMANCE OF ELECSYS ANTI-HEV IGG AND IGM ASSAYS FOR THE DETECTION OF ACUTE, RECENT, OR PAST HEPATITIS E VIRUS INFECTION Korbinian Kienle
  • Oral Presentation: REAL-WORLD IMPLEMENTATION OF POINT-OF-CARE (POC) HCV RNA TESTING IN A MOBILE UNIT IN HOMELESS ENCAMPMENTS AND SHELTERS IN ONTARIO, CANADA: IMPACT ON THE CASCADE OF CARE Lindsay Myles
  • Q&A
1:30 PM - 3:00 PMBeverlyPUBLIC HEALTH PARALLEL 5 - Hepatitis B, C, D elimination

Moderator: Huma Qureshi

  • Novel Interventions to Facilitate Hep C Elimination in Rural Settings (Integrating work on larger scale, randomized control trials, rural home test kits) Jennifer Havens
  • Addressing Barriers to Hepatitis B Screening in Low and Middle Income Settings Tanwandee Tawasek 
  • Oral Presentation: MODELING HEPATITIS C VIRUS ELIMINATION IN THE UNITED STATES: ARE WE ON TRACK TO REACH INCIDENCE TARGETS? Natasha Martin
    PROGRESS TOWARD HEPATITIS C ELIMINATION IN HIGH-INCOME COUNTRIES Homie Razavi
  • Oral Presentation: A COMPARATIVE ANALYSIS OF NATIONAL HBV ELIMINATION POLICIES, PROGRAMS, AND PROGRESS ACROSS INCOME LEVELS Jana Manning
  • Oral Presentation: MODELLING THE IMPACT AND COST-EFFECTIVENESS OF SCALING UP OF HCV CASE FINDING AND TREATMENT FOR ACHIEVING ELIMINATION AMONG PEOPLE WHO INJECT DRUGS IN ENGLAND Peter Vickerman
  • Q&A 
3:30 PM - 5:00 PMSan DiegoCLINICAL PARALLEL 8 - Overlapping Epidemics: Viral Hepatitis Meets Steatotic Liver Disease

Moderator: Edward Gane 

  • Alcohol and Viral Hepatitis: How Much is too Much? Jennifer Flemming
  • Risk of HCC in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Viral Hepatitis Mindie Nguyen
  • Oral Presentation: LOW VIRAL LOAD ASSOCIATED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AMONG PEOPLE LIVING WITH HEPATITIS B VIRUS (PLWHB) IN A DIVERSE CENTRAL LONDON CLINIC Emily Martyn
  • Oral Presentation: COMMON COMORBIDITIES IN PATIENTS WITH HEPATITIS C Hussain Asgarali
  • Q&A
3:30 PM - 5:00 PMSacramentoCLINICAL PARALLEL 9 - Remaining Challenges in Hepatitis C

Moderator: Gregory Dore

  • HCV : Improving care after HCV diagnosis and after HCV Cure  Jennifer Price
  • Treatment of HCV in Context of HCC - Remaining Challenges in 2025 Norah Terrault
  • Oral Presentation: A NATIONAL PROGRAM TO SCALE-UP POINT-OF-CARE TESTING AND TREATMENT FOR HEPATITIS C INFECTION IN AUSTRALIA, 2022-2024 Jason Grebely
  • Oral Presentation: HOW MUCH DAA TREATMENT IS ENOUGH? OUTCOMES FROM A LARGE CASE SERIES OF HCV TREATMENT INTERRUPTIONS Astha Kanani
  • Oral Presentation: ADHERENCE AND DOSE INTERRUPTIONS OF GLECAPREVIR/PIBRENTASVIR IN CHRONIC HCV PATIENTS WITH MULTIPLE COMORBIDITIES AND ON CONCOMITANT MEDICATIONS Jordan Feld
  • Q&A
3:30 PM - 5:00 PMBeverlyPUBLIC HEALTH PARALLEL 6 - Pathways towards Hepatitis Elimination

Moderator: Alexander Stockdale 

  • WHO Progress, and Next Steps toward hepatitis elimination Funmi Lesi 
  • Spain Javier Garcia-Samaniego
  • South Korea Su Jong Yu
  • Pakistan Saeed Hamid 
  • Plans, policies and progress toward  hepatitis elimination: Findings from 33 national profiles  Lindsey Hiebert 
  • Q&A
Time Location Name Name Description Speakers
8:30 AM - 10:00 AMSan DiegoBASIC PARALLEL 4 - Gene- and Cell therapies - latest news

Moderator: Ralf Bartenschlager

  • CAR-T cells in liver transplantation Elmar Jaeckel
    Gene correction in the liver using CRISPR  Alexander Ploss
  • CRMA-1001 AN EPIGENETIC EDITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B Yesseinia Anglero-Rodriguez
  • PBGENE-HBV DEFINITIVE PRECLINICAL TOXICOKINETIC AND TOXICOLOGY DATA ENABLES ADVANCEMENT TO CLINICAL TRIALS FOR A POTENTIALLY CURATIVE GENE EDITING TREATMENT FOR CHRONIC HEPATITIS B Emily Harrison
  • INHIBITING HDV BY ADENINE BASE EDITING OF HEPATITIS B SURFACE ANTIGEN Anuj Kumar
  • Q&A
     
8:30 AM - 10:00 AMSacramentoCLINICAL PARALLEL 10 - Special Populations in Viral Hepatitis

Moderator: Jordan Feld 

  • Immunocompromised Patients and Viral Hepatitis Management Karen Doucette
  • Management of Children with Viral Hepatitis (i.e., Immuntolerant or High Replicative, Non-Inflammatory) Ravi Jhavari
  • Oral Presentation: HEPATITIS B REACTIVATION AND TRANSMISSION OUTCOMES IN KIDNEY TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY Imran Hasanoglu
  • Oral Presentation: WHAT DO WE KNOW ABOUT GENDER AND AGE IN GLOBAL HEPATITIS C TREATMENT WITH SOF/VEL?  A STUDY OF 7,000 PATIENTS IN ASIA, LATIN Fatima Higuera
  • Oral Presentation: PREVALENCE OF VIRAL HEPATITIS IN SEXUAL MINORITIES IN THE UNITED STATES: A NATIONAL COHORT STUDY Tzu-Hao Lee
  • Q&A
8:30 AM - 10:00 AMSan JosePUBLIC HEALTH PARALLEL 7 - Panel Discussion: Innovations to Accelerate Hepatitis Elimination

Moderator: Jason Grebely

  • How to Implement New Diagnostic Technologies in the Field Boatemaa Ntiri-Reid
  • Access to the Latest Therapies Liudmyla Maistat 
  • The Roles of Communities of Practice: To Implement New Technologies & Strategies Sanjeev Arora
  • Panel Discussion + Q&A
10:30 AM - 12:00 PMSacramentoPLENARY 4 - State of the Art: Towards Achieving Health Equity, Closing Remarks & GHS 2027 Introduction

Moderator: John Ward and Norah Terrault

  • Australia Greg Dore 
  • UK David Leeman
  • Spain Camila Picchio 
  • Africa Ponsiano Ocama 
  • Morocco Ibtissam Khoudri
  • China Fuqiang Cui
  • Panel + Q&A
  • Closing Remarks Harry Janssen, Jordan Feld